Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $11.50

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $12.80.

Several brokerages have recently issued reports on INO. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. Oppenheimer decreased their target price on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday. Finally, Royal Bank of Canada decreased their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 15th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in shares of Inovio Pharmaceuticals during the second quarter worth $661,000. Dimensional Fund Advisors LP bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth $605,000. Wellington Management Group LLP acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth about $379,000. State Street Corp grew its position in shares of Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after buying an additional 51,414 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after buying an additional 38,833 shares during the period. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO opened at $1.98 on Friday. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75. The stock’s fifty day moving average is $3.42 and its 200 day moving average is $6.10. The stock has a market capitalization of $51.68 million, a P/E ratio of -0.95 and a beta of 0.84.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.